Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Anal Cancer Companies

ID: MRFR/MED/1001-HCR
130 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Several pharmaceutical and biotechnology companies are involved in the development of cancer therapies, including those targeting various types of cancers, such as anal cancer. Anal cancer is a relatively rare cancer that forms in the tissues of the anus. Treatments may include surgery, radiation therapy, and chemotherapy.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Anal Cancer Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)7.10%
2025 Market SizeUSD 1.04 Billion
2035 Market SizeUSD 2.06 Billion
Key Players
Incyte Corporation
Bristol-Myers Squibb
Merck & Co.
Roche/Genentech
Pfizer
AstraZeneca
Opportunities
  • Combination Immunotherapy Regimens
  • Therapeutic Vaccine Development
  • Asia-Pacific Screening Infrastructure Scale-Up

Top Industry Leaders in the Anal Cancer Market

Anal Cancer Companies
 

Latest Anal Cancer Companies Updates:

Oncolytics Biotech presented promising data at the ASH annual meeting regarding the combination of their drug pelareorep with the checkpoint inhibitor atezolizumab for advanced squamous cell carcinoma of the anus (SCCA). This could offer a new treatment option for this difficult-to-treat cancer.

Bristol Myers Squibb showcased several research findings on blood disorders and cell therapy at the ASH meeting, including potential advancements in immunotherapy for anal cancer.Virtu Market Research reported a projected value of USD 669.24 million for the Global Rapid Diagnostic Testing for Anal Cancer Market by 2030, indicating continued growth in demand for fast and accurate diagnosis.

List of Anal Cancer Key companies in the market:

  • Amgen Inc. (US)
  • Bristol-Myers Squibb Company (US)
  • Celgene Corporation (US)
  • Eli Lilly and Company (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co., Inc. (US)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Sanofi (France)